Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
Model-fitted parameter estimates were used to derive suggested loading and maintenance dosing regimens for various categories of patients, including those on hemodialysis and continuous renal replacement, and colistin may best be used as part of a highly active combination.
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production
- Jennifer H. Moffatt, M. Harper, J. Boyce
- BiologyAntimicrobial Agents and Chemotherapy
- 20 September 2010
It is shown that A. baumannii can rapidly develop resistance to polymyxin antibiotics by complete loss of the initial binding target, the lipid A component of lipopolysaccharide (LPS), which has long been considered to be essential for the viability of Gram-negative bacteria.
Structure--activity relationships of polymyxin antibiotics.
This research presents a novel and scalable approaches that allow for real-time decision-making in the design and implementation of drug 505(b) agonist regimens for the treatment of central nervous system disorders.
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
- A. M. Sandri, C. Landersdorfer, A. Zavascki
- Medicine, BiologyClinical infectious diseases : an official…
- 22 May 2013
This study showed that doses of intravenous polymyxin B are best scaled by total body weight, and dosage selection of this drug should not be based on renal function.
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
- A. Zavascki, L. Goldani, J. Li, R. Nation
- Medicine, BiologyThe Journal of antimicrobial chemotherapy
- 1 December 2007
Since polymyxins will be increasingly used for the treatment of infections caused by MDR bacteria, clinical pharmacokinetic, pharmacodynamic and toxicodynamic studies underpinning the optimal use of these drugs are urgently required.
Colistin and polymyxin B: peas in a pod, or chalk and cheese?
The view that overall polymyxin B has superior clinical pharmacological properties compared with CMS/colistin is put forth, and it is proposed that in countries such as the United States where parenteral products of both colistin and polymyXin B are available, prospective studies should be conducted to formally examine their relative efficacy and safety in various types of infections and patients.
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
These findings give a strong warning that colistin-resistant A. baumannii may be observed more frequently due to potential suboptimal dosage regimens recommended in the product information of some products ofcolistin methanesulfonate.